Silver Spring’s United Therapeutics Corporation provided an update on Mr. David Bennett, the first UHeart™ recipient, stating that “The recent transplants of our xenoheart and xenokidney products demonstrate the tremendous potential of our business model for the second half of the 2020s and beyond. Indeed, Mr. David Bennett, Sr., the first UHeart™ recipient, continues to have strong cardiovascular function seven weeks after his transplant.”
The surgery took place at the University of Maryland Medical Centre (UMMC). It was a first of its kind transplant of a genetically modified pig heart that was successfully carried out in David Bennett, a 57-year-old man with terminal heart disease.